Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.